Drug intelligence / Profile preview

Kolofort

Development stage
Phase 4
Lead developer
Materia Medica Holding
Modality
Small Molecules, Antibody-Based Therapeutics
Administration
Sublingual
01

Overview

Kolofort is a pharmaceutical drug formulated as sublingual tablets for the treatment of irritable bowel syndrome (IBS) and functional dyspepsia. It contains low doses of affinity-purified antibodies to three targets: tumor necrosis factor alpha (TNF-α), histamine, and S100 brain-specific protein. The mechanism of action involves modulation of immune responses and inflammation by targeting TNF-α, regulation of gastrointestinal motility via histamine H4 receptors in the gut, and psychotropic effects through interaction with serotonin receptors and sigma-1 receptors in the central nervous system. This combination provides spasmolytic, anti-inflammatory, anxiolytic, antidepressive, antiasthenic, nootropic, and sedative effects that help normalize gastrointestinal function. Kolofort is primarily indicated for IBS (including stress-related forms) and functional dyspepsia manifested by symptoms such as abdominal pain, constipation or diarrhea, flatulence, bloating, nausea or vomiting[1][2][3][5][6].

Brand names
Kolofort
02

Targets

S100B (S100 Calcium-Binding Protein B)TNFA (Tumor necrosis factor alpha (soluble))HRH4 (Histamine H4 receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on Kolofort.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kolofort.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call